\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United States and Canada for Rett syndrome in adults and pediatric patients two years of age and older.<\/p>\n
\n\u201cThis application underscores our continued dedication to the Rett community, and our commitment to making a meaningful impact for people living with Rett syndrome and their caregivers in the EU, who currently have no approved treatment options specifically for this condition,\u201d said Catherine Owen Adams, Acadia\u2019s Chief Executive Officer. \u201cWe look forward to working with the EMA to address this unmet need in the hopes of potentially bringing this therapy to families who are impacted by Rett syndrome.\u201d<\/p>\n
\nThe MAA is supported by positive results from the pivotal Phase 3 LAVENDER\u2122 study evaluating the efficacy and safety of trofinetide versus placebo in 187 girls and young women five to 20 years of age with Rett syndrome. The co-primary endpoints were change from baseline in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score, a caregiver assessment, and Clinical Global Impression\u2013Improvement (CGI-I) scale score, clinician perspective, at week 12; both were statistically significant. The RSBQ is a 45-item rating scale completed by the caregiver that assesses a range of symptoms of Rett syndrome (breathing, hand movements or stereotypies, repetitive behaviors, night-time behaviors, vocalizations, facial expressions, eye gaze, and mood). The key secondary endpoint measuring the change from baseline to week 12 in the Communication and Symbolic Behavior Scales Development Profile\u2122 Infant-Toddler Checklist\u2013Social composite score (CSBS-DP-IT\u2013Social) was also statistically significant when compared to placebo.1<\/sup><\/p>\n \n\u201cRett syndrome is a severe and complex neurodevelopmental disorder that manifests differently in each affected person, leading to a wide range of symptoms over the course of their lives,\u201d said Becky Jenner, President of Rett Syndrome Europe. \u201cThe Rett syndrome community in Europe is excited by the prospect of having an available treatment option. Rett syndrome has a significant impact on people living with this condition, and also impacts caregivers and families who often have to navigate challenging symptoms that impact their daily lives.\u201d<\/p>\n About Rett Syndrome<\/i><\/p>\n \nRett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and occurs in approximately one of every 10,000 to 15,000 female births worldwide.2-4 <\/sup>A child with Rett syndrome exhibits an early period of apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration which can last the rest of the patient\u2019s life.3<\/sup> Rett syndrome is typically caused by a genetic mutation on the MECP2<\/i> gene.5 <\/sup>In preclinical studies, deficiency in MeCP2function is thought to lead to impairment in synaptic communication, and the deficits in synaptic function may be associated with Rett manifestations.5-7<\/sup><\/p>\n \nSymptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and clapping, and gait abnormalities.8<\/sup> Most people living with Rett syndrome typically live into adulthood and require round-the-clock care.2,9<\/sup><\/p>\n About Trofinetide<\/i><\/p>\n \nTrofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.10<\/sup><\/p>\n About Acadia Pharmaceuticals Inc.<\/i><\/p>\n \nAcadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson\u2019s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer\u2019s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n Forward-Looking Statements<\/i><\/p>\n \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cpotential\u201d and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the potential approval of trofinetide as the first option in the European Union for the treatment of Rett syndrome, (ii) the efficacy and safety profile of trofinetide for patients with Rett syndrome, (iii) market acceptance in EU, including the importance of trofinetide for the treatment of Rett syndrome, if approved, for Rett patients or families of patients with Rett syndrome and (iv) the ability for trofinetide to address the unmet medical needs of Europeans living with Rett syndrome. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: the ability for trofinetide to deliver efficacious and safe results to patients, if approved, our dependency on the continued successful commercialization of DAYBUE\u2122 in the United States and Canada, where it is approved, our ability to obtain regulatory approval of trofinetide in the EU or other jurisdictions outside the United States and Canada, our ability to protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions, and other factors that may cause our actual results, performance or achievements to differ, please refer to our quarterly report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.<\/p>\n References View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250114935731\/en\/<\/a><\/span><\/p>\n Investor Contact: Media Contact: KEYWORDS:<\/b> Europe United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Health Mental Health Genetics Clinical Trials<\/p>\n
\n
<\/i>1 <\/sup>Neul JL, Percy AK, Benke TA et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med<\/i>. 2023; 29: 1468\u20131475
\n
2<\/sup> Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open<\/i>. 2020; 4: 1-14.
\n
3 <\/sup>Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol<\/i>. 2018; 8: 170216.
\n
4<\/sup> May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J of Med Econ<\/i>. 26(1), 1570\u20131580.
\n
5<\/sup> Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet<\/i>. 1999; 23(2): 185-188.
\n
6<\/sup> Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol<\/i>. 2005; 64(6): 537-544.
\n
7<\/sup> Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis<\/i>. 2006; 21(1): 217-227.
\n
8<\/sup> Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol<\/i>. 2010; 68(6): 944-950.
\n
9<\/sup> Daniel C, Tarquinio DO, Hou W, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol<\/i>. 2015; 53(5): 402-411.
\n
10<\/sup> Acadia Pharmaceuticals Inc., Data on file.<\/p>\n<\/p>\n
\n<\/i>
Acadia Pharmaceuticals Inc.
\n
Al Kildani
\n
(858) 261-2872
\n
ir@acadia-pharm.com
\n<\/a><\/p>\n
\n<\/i>
Acadia Pharmaceuticals Inc.
\n
Deb Kazenelson
\n
(818) 395-3043
\n
media@acadia-pharm.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250114935731\/en\/2329845\/3\/Logo_Acadia_Reg.jpg\"){kind=logo}
<\/td>\n<\/tr>\n